PRINCETON, N.J. and ROCKVILLE, Md./PRNewswire/ -- RadPharm Inc., a leading Imaging Core Laboratory, and Medifacts International, Inc., a leading Cardiovascular Core Laboratory, have announced the merger of their business operations. The combined company will be named CoreLab Partners ("CoreLabs") and will have its corporate headquarters in Princeton, New Jersey.
The combination of RadPharm and Medifacts brings together two best-in-class companies and creates one of the largest independent core labs serving the market today. The CoreLabs global footprint comprises more than 400 employees and includes offices with operational capabilities in North America, Europe, and Asia. The company has leveraged this worldwide infrastructure to support over 100 sponsors, including a wide range of pharmaceutical, biotech, medical device and contract research organizations, and more than 450 clinical trials in 60 countries.
RadPharm and Medifacts address distinctive, attractive segments of the pharmaceutical outsourcing market through a complementary core lab business model. Oncology and Cardiovascular drug programs are two of the highest growth segments of the clinical trials services market. CoreLabs will offer drug sponsors and their CRO partners a much deeper suite of cost-effective services solutions across a substantially broader range of modalities and therapeutic indications.
Ad Statistics
Times Displayed: 173763
Times Visited: 3176 For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
Commenting on the merger, Michael Woehler, PhD, President and Chief Executive Officer of CoreLab Partners, said, "As they seek to gain cost advantages over their competitors, drug development companies and contract research organizations continue to shift their paradigm by streamlining their outsourcing functions and partnering with a smaller universe of key vendor relationships. I am confident that the financial scale and organizational strength of the combined RadPharm and Medifacts teams will provide our clients with the comfort of knowing that their clinical trials will be completed on time, without interruption, at the highest levels of quality and efficiency."
Woehler continued, "Pharmaceutical and biotech companies today are seeking strategic partnerships with vendors who can be trusted to deliver high-quality service and who have experience in getting drugs approved by regulatory agencies around the world. CoreLab Partners brings together two teams with focused, global capabilities and proven track records of operational excellence and therapeutic expertise."
